Trial Profile

HyPeR: A Phase 1, Dose Escalation Study of Guadecitabine /ASTX727 in Combination With Pembrolizumab (MK3475) in Patients With Refractory Solid Tumours

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Guadecitabine (Primary) ; Pembrolizumab (Primary)
Indications Non-small cell lung cancer; Prostate cancer; Solid tumours
Focus Adverse reactions
Acronyms HyPeR

Most Recent Events

17 Aug 2025 Planned number of patients changed from 34 to 60.
19 Mar 2024 Status has been to recruiting.
17 Oct 2023 Number of treatment arms have been increased from 2 to 3 by the addition of Experimental: B2: Lung Expansion arm.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com